Browsing Tag
clinical-stage biotech
3 posts
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Pasithea Therapeutics raises $60m in discounted public offering as biotech funding momentum returns
Find out how Pasithea Therapeutics’ $60 million stock offering reshapes its clinical runway, dilution outlook, and investor sentiment.
Can Incannex Healthcare’s dual breakthrough in OSA and anxiety therapy lift IXHL shares in 2025?
Discover how Incannex Healthcare is converting major trial wins and smart capital moves into a stronger 2025 growth plan!